IMNM Earnings Preview

Redmile Doubles Down on Clinical Biotech Upswing

Redmile's concentrated bet — now its 9th largest position — suggests the fund believes Immunome's Phase 3 data is durable enough to justify a 9% weighting in a diversified biotech portfolio. The positioning matters: an 18-month rally followed by institutional capital backing doesn't guarantee approval (regulatory risk remains), but it signals the market is pricing a meaningful probability of success.

Watch: The path to varegacestat approval — Immunome will need to file and navigate FDA review, likely 12-18 months out. Watch also for any Phase 3 data readouts from the rest of the pipeline and whether the $400 million burn rate sustains clinical progress without another dilutive raise.